Wuhan Hiteck Biological Pharma Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 7.97%

Wuhan Hiteck Biological Pharma Co Ltd (300683) has an Asset Resilience Ratio of 7.97% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300683 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥196.94 Million

≈ $28.82 Million USD Cash + Short-term Investments

Total Assets

CN¥2.47 Billion

≈ $361.62 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300683 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Wuhan Hiteck Biological Pharma Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 300683 current and long-term liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥196.94 Million	7.97%
Total Liquid Assets	CN¥196.94 Million	7.97%

Asset Resilience Insights

Limited Liquidity: Wuhan Hiteck Biological Pharma Co Ltd maintains only 7.97% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Wuhan Hiteck Biological Pharma Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wuhan Hiteck Biological Pharma Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Wuhan Hiteck Biological Pharma Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	6.62%	CN¥170.63 Million ≈ $24.97 Million	CN¥2.58 Billion ≈ $377.03 Million	-8.69pp
2024-12-31	15.31%	CN¥449.69 Million ≈ $65.80 Million	CN¥2.94 Billion ≈ $429.72 Million	+15.30pp
2023-12-31	0.01%	CN¥303.97K ≈ $44.48K	CN¥2.97 Billion ≈ $434.79 Million	-5.31pp
2022-12-31	5.32%	CN¥144.04 Million ≈ $21.08 Million	CN¥2.71 Billion ≈ $396.03 Million	-13.75pp
2021-12-31	19.07%	CN¥514.40 Million ≈ $75.27 Million	CN¥2.70 Billion ≈ $394.73 Million	+7.62pp
2020-12-31	11.45%	CN¥250.39 Million ≈ $36.64 Million	CN¥2.19 Billion ≈ $319.96 Million	-10.65pp
2019-12-31	22.11%	CN¥479.57 Million ≈ $70.18 Million	CN¥2.17 Billion ≈ $317.47 Million	--

pp = percentage points

About Wuhan Hiteck Biological Pharma Co Ltd

SHE:300683 China Drug Manufacturers - Specialty & Generic

Market Cap

$480.19 Million

CN¥3.28 Billion CNY

Market Cap Rank

#12564 Global

#3683 in China

Share Price

CN¥25.07

Change (1 day)

+2.58%

52-Week Range

CN¥22.76 - CN¥48.78

All Time High

CN¥84.19